NEOSTIGMINE METHYLSULFATE INJECTION MARKET ANALYSIS

Market News

Recent Developments

New product launches

• Hikma Pharmaceuticals, a U.K.-based pharmaceutical company, announced the launch of Neostigmine Methylsulfate Injection, USP in prefilled syringe (PFS) form in the U.S. in 2022. This is a cholinesterase inhibitor, indicated for the reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBAs) after surgery.
• Endo International, a U.S.-based global generic and specialty branded drug pharmaceutical company, launched PREVDUO (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe in the U.S. in 2023. This is the first and only U.S. Food and Drug Administration (FDA) approved neostigmine glycopyrrolate combination product in the U.S. It is indicated for the reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBAs) after surgery.

Acquisitions and partnerships

• Pfizer Inc.: In 2021, Pfizer Inc., a U.S.-based global pharmaceutical company, announced the acquisition of Anacor Pharmaceuticals, a biopharmaceutical company that specializes in the development and commercialization of dermatological therapies. Anacor Pharmaceuticals had a neostigmine methylsulfate injection product in its portfolio.
• Mylan: In 2020, Mylan, a U.S.-based global generic and specialty pharmaceuticals company, announced the acquisition of Agila Specialties, a pharmaceutical company that specializes in the development and commercialization of generic injectable products. Agila Specialties had a neostigmine methylsulfate injection product in its portfolio.